A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
← catalyst calendarNCT07037758 · readout in 577 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →. With Asher Biotherapeutics, Inc..
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
380estimated
Sites
19
Countries
South Korea, Turkey (Türkiye), United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-16 | actual | When the study began enrolling |
| Primary completion | 2028-03-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-01-18 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Extensive Stage Small Cell Lung Cancer
Interventions
- Drug: Tarlatamab — also filed as AMG 757, Imdelltra
- Drug: AB248
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Treatment-emergent Adverse Events (TEAEs)
measured Up to 2.5 years
Dose Exploration: Number of Participants with Dose-limiting Toxicities (DLTs)
measured Up to 35 days
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed